Expert Opinion on Drug Safety

Article	Citations
Novel insights into post-marketing AEs associated with bempedoic acid: a comprehensive analysis utilizing the FAERS database	119
Resistance to hedgehog inhibitors in basal cell carcinoma: strategies to adopt	99
Adverse event profiles of drug-induced decreased libido: an assessment of the US food and drug administration Adverse Event Reporting System	86
An update on the cognitive safety of antimuscarinics in the treatment of overactive bladder	79
Hypogammaglobulinemia and infections in patients with multiple sclerosis treated with anti-CD20 monoclonal antibodies: a systematic review and meta-analysis of observational studies	50
Drug-induced hepatitis B virus reactivation: insights from FAERS database analysis	45
Adverse events in patients with cardiovascular disease taking proton pump inhibitors	44
Exploration and evaluation of adverse event signals of droxidopa based on the FAERS database	42
Infectious events in patients with alopecia areata treated with JAK inhibitors: low burden and minimal impact on persistence in treatment	35
Comparison of adverse events of poly adenosine diphosphate ribose polymerase inhibitors in patients with ovarian cancer using the United States Food and Drug Administration Adverse Event Reporting Sys	32
Safety profile of isocitrate dehydrogenase inhibitors in cancer therapy: a pharmacovigilance study of the FDA Adverse Event Reporting System	32
Exploration of cardiac adverse events associated with relugolix and degarelix: a multi-center pharmacovigilance study based on the FAERS database	29
Assessment of adverse events related to anti-interleukin-6 receptor monoclonal antibodies using the FDA adverse event reporting system: a real-world pharmacovigilance study	28
Mechanism and clinical utility of abatacept in the treatment of rheumatoid arthritis	27
The role of artificial intelligence in pharmacovigilance for rare diseases	27
Why is pharmacovigilance essential for biosimilars?	26
The safety of phthalate-containing medications used during pregnancy	26
Safety assessment of brexanolone in the FAERS database: real adverse event analysis and discussion of side effects	25
Assessment of adverse events of the novel antiepileptic drug lamotrigine: a real-world pharmacovigilance study based on FAERS	23
Long-term safety of ketamine and esketamine in treatment of depression	22
An updated safety review of Hidradenitis Suppurativa treatment options	21
A real-world pharmacovigilance study of QT interval prolongation and Torsades de Pointes associated with CDK4/6 inhibitors in breast cancer patients: findings from the FDA adverse event reporting syst	20
Underuse of GLP-1 receptor agonists in the management of type 2 diabetes despite a favorable benefit-safety profile	20
The effectiveness and safety of aripiprazole, bromocriptine, and cabergoline in the treatment of hyperprolactinemia: a systematic review and network meta-analysis	19
Pharmacovigilance approaches to study rare and very rare side-effects: the example of clozapine-related DiHS/DRESS syndrome	19

The safety profile of azithromycin in pediatrics: a pharmacovigilance disproportionality analysis	19
The Impact of Medication Regimen Complexity Score on Multi-Organ Dysfunction and Clinical Outcomes in Critically Ill Patients: A Cohort Study	19
A safety review of approved oral agents for treating type 2 diabetes and associated diseases in pregnant patients	18
Newly identified adverse events of enzalutamide using the food and drug administration adverse event reporting system	18
Diarrhea-predominant irritable bowel syndrome treatment options eluxadoline, rifaximin, and alosetron: analysis of the FDA adverse event reporting system (FAERS) database	18
Risk of acute kidney injury in patients receiving vancomycin and concomitant piperacillin-tazobactam or carbapenem: a multicenter, retrospective cohort study	18
Safety and efficacy of anti-SARS-CoV-2 monoclonal antibodies in pregnancy	17
Comparative disproportionality analysis of adverse events associated with combined therapy versus monotherapy of abiraterone and olaparib for prostate cancer: a pharmacovigilance study using the FAERS	17
Safety and efficacy of anticoagulant administration in people with atrial fibrillation and advanced chronic kidney disease	17
Correction	17
Safety concerns associated with BACE1 inhibitors – past, present, and future	17
Unveiling the hidden ocular risks of isotretinoin: a comprehensive FAERS-Based analysis	17
Does the use of generative AI chatbots by patients introduce risk of adverse drug events?	16
Update of safety profile of levonorgestrel: a disproportionality analysis based on FAERS from 2004 to 2023	16
A real-world disproportionality analysis of baloxavir marboxil: post-marketing pharmacovigilance data	16
First-time adverse drug reactions, survival analysis, and the share of adverse drug reactions in treatment discontinuation in real-world rheumatoid arthritis patients: a comparison of first-time treat	16
Angioedema risk of thrombolytics: an integrated assessment using disproportionality analysis of the USFDA adverse event reporting system, case reviews and meta-analysis	16
Disease-specific ADRs of TNF-α inhibitors as reported by patients with inflammatory rheumatic diseases: a registry-based prospective multicenter cohort study	16
SSRI withdrawal syndrome in children and adolescents: a narrative literature review	15
Sodium-glucose cotransporter-2 inhibitors and cardiovascular safety profile: a pharmacovigilance analysis of the US food and drug administration adverse event reporting system	15
Post-marketing safety concerns with palbociclib: a disproportionality analysis of the FDA adverse event reporting system	15
Safety and effectiveness of empagliflozin in Japanese patients with type 2 diabetes: final results of a 3-year post-marketing surveillance study	15
Post-marketing safety evaluation of zanubrutinib: a real-world pharmacovigilance analysis based on the FAERS database	15
Corticosteroids for the treatment of Duchenne muscular dystrophy: a safety review	14
Hallucinations and delusions associated with Parkinson’s disease psychosis: safety of current treatments and future directions	14
Tirzepatide and glucagon-like peptide-1 receptor agonists: safety always comes first!	14
Safety of intranasal corticosteroids for allergic rhinitis in children	14
Comparative analysis of CDKI-related adverse events in older patients: a real-world data from the FDA adverse event reporting system database	14
Long-term safety and effectiveness of vonoprazan for prevention of gastric and duodenal ulcer recurrence in patients on nonsteroidal anti-inflammatory drugs in Japan: a 12-month post-marketing surveil	13
Data pharmacovigilance analysis of medroxyprogesterone-related adverse events in the FDA adverse event reporting system	13
Gastrointestinal adverse events associated with immune checkpoint inhibitors: a pharmacovigilance analysis of the EudraVigilance and VigiAccess databases	13
Data mining for signal detection of adverse events for taxanes based on the food and drug administration adverse drug events reporting system database	13
Safety of current antiviral drugs for chronic hepatitis B	13
Long-term safety profile and secondary effectiveness of canakinumab in pediatric rheumatic diseases: a single-center experience	12
Cardiovascular adverse events in patients with HER2-positive breast cancer treated with trastuzumab-drug conjugates : a Bayesian disproportional real world study for signal detection leveraging the FD	12
Exploration of the clinical characteristics and potential mechanisms of liver injury induced by proton pump inhibitors	12
Drug-induced myocarditis: a real-world pharmacovigilance study using the FDA adverse event reporting system database	12
Safety considerations for drugs newly approved for treating acute myeloid leukemia	12
How do safety warnings on medicines affect prescribing?	12
Adverse events associated with acute pancreatitis caused by immune checkpoint inhibitors: a pharmacovigilance analysis of the FDA adverse event reporting system (FAERS) database	12
Antibody-drug conjugates-related interstitial lung diseases: data mining of the FAERS database	12
Treatment free remission (TFR) after second-generation tyrosine kinase inhibitors (2G-TKIs) treatment in chronic myeloid leukemia (CML): from feasibility to safety	12
Development and validation of a nomogram to predict the risk of potentially inappropriate medication use in older lung cancer outpatients with multimorbidity	12
The use of hydroxyurea in the real life of MIOT network: an observational study	12
Influence factors of metronidazole-related CNS disorders: an analysis of the Japan adverse drug event report and FDA adverse event reporting system	12
Differences in safety profiles of anti-herpesvirus medications: a real-world pharmacovigilance study based on the FAERS database	12
Drug-induced erectile dysfunction: a real-world pharmacovigilance study using the FDA adverse event reporting system database	12
Current safety concerns about the use of antiseizure medications in pregnancy	12
Drug safety evaluation of ixekizumab for psoriasis: a review of the current knowledge	12
Long-term safety of lanthanum carbonate in the real word: a 19-year disproportionality analysis from the FDA Adverse Event Reporting System	12

Anticoagulant-associated calciphylaxis: analysis of USFDA adverse event report system and clinical feature analysis of reported cases	12
Association between dual orexin receptor antagonists (DORAs) and suicidality: reports to the United States Food and Drug Administration Adverse Event Reporting System (FAERS)	12
Assessment of adverse events of tasimelteon: a real-world pharmacovigilance study based on FAERS	12
Disproportionality analysis of the safety profile of rufinamide in the real world: an evaluation of the FDA Adverse Event Reporting System database	12
Vancomycin and linezolid: severe cutaneous adverse reactions to drugs	12
Drug-induced hyperacusis: a disproportionality analysis of the FAERS database	11
Comparative effectiveness and safety of drug therapy for chronic urticaria: a network meta-analysis and risk-benefit assessment	11
Adverse event signal analysis of type Ib MET tyrosine kinase inhibitors based on food and drug administration adverse event reporting system	11
Hemorrhage profile associated with immune checkpoint inhibitors: a systematic review and a real-world study based on the FAERS database	11
Adverse events associated with inclisiran: a real-world disproportionality analysis based on the FAERS database	11
Safety of marketed biosimilar monoclonal antibody cancer treatments in the US: a disproportionality analysis using the food and drug administration adverse event reporting system (FAERS) database	11
Adverse events associated with aromatase inhibitors: an analysis of real-world datasets and drug-gene interaction network	10
Updated insights on levetiracetam-associated severe cutaneous adverse reactions: a real-world pharmacovigilance analysis	10
Will the future of pharmacovigilance be more automated?	10
Adverse event profile of ocular injury associated with JAK inhibitors in patients with rheumatoid arthritis: a disproportionality analysis	10
Ocular toxicities associated with antibody drug conjugates and immunotherapy in oncology: clinical presentation, pathogenesis, and management strategies	10
The importance and utility of post market drug safety monitoring in cancer therapy	10
Congenital anomalies associated with the use of cardiovascular drugs during pregnancy: a large-scale data analysis from the FAERS database	10
Adverse events of direct factor Xa inhibitors: a disproportionality analysis of the FAERS database	10
The effectiveness and safety of naldemedine in treating opioid-induced constipation among non-cancer adult patients: updated meta-analysis	10
Reply to Letter to the Editor regarding “Drug-induced noninfectious myocarditis: a disproportionality analysis of the FAERS database”	9
Safety evaluation of ILaris: a real-world analysis of adverse events based on the FAERS database	9
Investigating bleeding adverse events associated with BTK inhibitors in the food and drug administration adverse event reporting system (FAERS)	9
A real‑world pharmacovigilance study of FDA adverse event reporting system events for daratumumab	9
Impact of preoperative pharmaceutical care consultation on medication errors in surgical patients: a comprehensive analysis	9
What’s in a name? What shall we call xanomeline-trospium combination?	9
Potential drugs for reducing the occurrence of immune checkpoint inhibitor-induced interstitial lung disease: an exploratory study using the JADER and FAERS databases	9
Treating psychosis in people with Parkinson’s disease	9
Generic pharmaceuticals, regulatory aspects, bioequivalence investigation, and perception	9
A review on side effect management of second-generation antipsychotics to treat schizophrenia: a drug safety perspective	9
Utility and limitations of the FDA adverse events reporting system public dashboard for safety analyses: a case study with vesicular monoamine transporter 2 inhibitors	8
Detection of risk signals for ustekinumab in the real world using the FDA Adverse Event Reporting System (FAERS)	8
Completeness of pharmaceutical industry insulin adverse event reports from Africa and the Middle East	8
Skin cancer associated with calcineurin inhibitors treatment: analysis of FAERS database	8
Comparing musculoskeletal and connective tissue disorder risks of teriparatide and abaloparatide in osteoporosis: an analysis based on FDA adverse event reporting system (FAERS)	8
COVID-19 vaccine safety studies- the need for a third group for extended monitoring	8
Analysis of the relationship between histamine H1 receptor antagonists and broad dementia events using the FAERS, JADER, and CVAR databases	8
The Safety, Efficacy, and Clinical Use of Novel Once-Weekly Insulins in the Management of Diabetes	8
Biosimilars and immunogenicity: a matter of concern?	8
Drug-induced dementia: a pharmacovigilance analysis of the FAERS database	8
Cognitive dysfunction following finasteride use: a disproportionality analysis of the global pharmacovigilance database	7
Safety evaluation of secukinumab in pediatric patients with plaque psoriasis	7
Hepatobiliary disorders and Direct-Acting Antiviral (DAA) therapies: real-world evidence and insights from the EudraVigilance database	7
Ocular adverse events of cenegermin used in neurotrophic keratopathy: an analysis of the FDA adverse event reporting system database	7
Liver toxicity in oncology trials and beyond: a simplified concept for management of hepatocellular drug-induced liver injury in patients with abnormal baseline liver tests	7
Safety of medications for hereditary angioedema during pregnancy and lactation	7
An update on the safety of ixazomib for the treatment of multiple myeloma	7
Efficacy and safety of biologics and small molecules for psoriasis in pediatric and geriatric populations. Part I: focus on pediatric patients	7
Dupilumab in real-life settings: a review of adverse events and their pathogenesis	7
Seizures associated with antibiotics: a real-world disproportionality analysis of FAERS database	7
Contributory factors and patient harm including deaths associated direct acting oral anticoagulants (DOACs) medication incidents: evaluation of real world data reported to the National Reporting and L	7
Comparative evaluation of adverse drug reactions for tenofovir alafenamide and tenofovir disoproxil fumarate using the FAERS Database: a disproportionality analysis	7
Comparison of four criteria for potentially inappropriate medications in older patients with newly diagnosed non-small cell lung cancer	7
The role of co-morbidities in the development of an AEFI after COVID-19 vaccination in a large prospective cohort with patient-reported outcomes in the Netherlands	7
Clozapine may consistently protect from suicidal behaviors while other antipsychotics may lack a specific protective effect: a comprehensive VigiBase study interpreted in the context of the prior lite	7
Effects of adding adjuvants to propofol on the post-anesthesia cognitive function in patients undergoing gastroscopy/colonoscopy: a systematic review and meta-analysis	7
A new paradigm in adverse drug reaction reporting: consolidating the evidence for an intervention to improve reporting	7
Cardiovascular toxicities of selective ret-specific tyrosine kinase inhibitors: a pharmacovigilance study based on the United States Food and Drug Administration Adverse Event Reporting System databas	7
Drug-induced nephrolithiasis: a real-world pharmacovigilance study of the FDA Adverse Event Reporting System	7
Study on analgesic-induced endocrine gland damage and its potential mechanisms	7
Safety issues of psilocybin and LSD as potential rapid acting antidepressants and potential challenges	7
Reporting of tumor lysis syndrome with targeted therapy for hepatic cancer in the FDA adverse events reporting system	7
Real-world safety evaluation of brivaracetam: insights from the US FDA Adverse Event Reporting System	7
Risk factors analysis and construction of predictive models for acute kidney injury in overweight patients receiving vancomycin treatment	7
Definition of treatment resistant psoriasis and related safety concerns	7
Opioid-related adverse drug events in surgical patients: risk factors and association with clinical outcomes	7
The efficacy and safety of Capivasertib (AZD5363) in the treatment of patients with solid tumor: a systematic review and meta-analysis of randomized clinical trials	7
Safety profiles of tetracycline-class drugs: a pharmacovigilance analysis of the FAERS database	7
The impact of the COVID-19 pandemic on adverse events associated with ACEIs and ARBs: a real-world analysis using the FDA adverse event reporting system	7
Post-marketing safety surveillance of Amivantamab: a real world study based on the FDA adverse event reporting system	6
Oral isotretinoin for acne: a complete overview	6
Signal mining and gender differences analysis of adverse events in NMIBC treatment with gemcitabine and BCG bladder instillation based on the FAERS database	6
Barriers and facilitators for systematically registering adverse drug reactions in electronic health records: a qualitative study with Dutch healthcare professionals	6
Adverse events associated with inclisiran: a real-world pharmacovigilance study of FDA adverse event reporting system (FAERS)	6
Letter to the Editor in response to: “Drug-induced noninfectious myocarditis: a disproportionality analysis of the FAERS database”	6
A retrospective study to evaluate Hy’s Law, DrILTox ALF score, Robles-Diaz model, and a new logistic regression model for predicting acute liver failure in Chinese patients with drug-induced liver inj	6
Safety assessment of tafamidis: a real-world adverse event analysis from the FAERS database	6
Potential side effects of currently available pharmacotherapies in male lower urinary tract symptoms suggestive of benign prostatic hyperplasia	6
Approved treatments for neovascular age-related macular degeneration: current safety and future directions	6
Correction	6

COMfort Eye Trial (COMET) results - a non-inferiority, randomized, investigator-masked, two-parallel group, phase III clinical trial, to evaluate the efficacy and safety of a preservative free formula	6
Can the revival of serotonergic psychedelic drugs as treatments for mental disorders help to characterize their risks and benefits?	6
Postmarketing safety of [ 177 Lu]Lu-PSMA-617 radioligand therapy for prostate cancer: a disproportionality analysis of the FDA adverse event reporting system	6
A real-world pharmacovigilance study of blinatumomab based on the FDA adverse event reporting system	6
Concomitant use of sodium-glucose co-transporter 2 inhibitors and metformin and the risk of osteomyelitis reporting: a disproportionality analysis based on FAERS database	6
Injection site reactions resulting from the use of biological therapy in the treatment of moderate-to-severe plaque psoriasis	6
Comparison of safety of acetaminophen and ibuprofen in minors: based on the FAERS database	6
Analyzing the patterns of adverse drug reactions due to anti-infectives from large-scale nationwide database in Thailand	6
The therapeutic potential of psilocybin: a systematic review	6
Immune checkpoint inhibitor related myositis: an observational, retrospective, pharmacovigilance study	6
Drug-induced Stevens-Johnson syndrome: a disproportionality analysis from the pharmacovigilance database of the World Health Organization	6
Investigating the risk of deep vein thrombosis with JAK inhibitors: a disproportionality analysis using FDA Adverse Event Reporting System Database (FAERS)	6
Intraocular inflammation as a major adverse event of anti-vascular endothelial growth factor therapy for neovascular age-related macular degeneration: from clinical trials to real-world practice	6
Cardiovascular adverse events associated with EGFR and HER2 dual TKIs: a pharmacovigilance study based on the FAERS database	6
Characteristics of adverse drug reactions induced by flutamide and bicalutamide: a real-world pharmacovigilance study using FAERS	6
Incidence, clinical characteristics and related drugs analyzing of drug-induced movement disorders in 102914 inpatients: a retrospective real-world study	6
Safety analysis of fluoroquinolone drugs in elderly patients over 65 based on FAERS	5
Suspected statin-related adverse drug reactions: analysis of spontaneous reports in Hubei Province, China (2014–2022)	5
Examining the safety of belimumab, especially in children: an analysis of real-world pharmacovigilance data from the US FDA adverse event reporting system (FAERS) database	5
A real-world pharmacovigilance case/non-case study of FDA adverse event reporting system events for mannitol	5
Neural dysfunction, inflammatory disorder, and metabolic interference feature in amantadine-related adverse drug events: a perspective from FAERS and network toxicology	5
Assessment of safety profile of ivabradine in real-world scenario using FDA adverse event reporting system database	5
Risk factors, prevention and treatment of weight gain associated with the use of antidepressants and antipsychotics: a state-of-the-art clinical review	5
Management of refractory checkpoint inhibitor-induced colitis	5
The safety and efficacy of sugammadex for reversing neuromuscular blockade in younger children and infants	5
Appropriateness of psychopharmacological therapies to psychiatric diagnoses in persons with autism spectrum disorder with or without intellectual disabilities: a cross-sectional analytic study	5
Is the psychedelic experience an essential aspect of the therapeutic effect of serotonergic psychedelics? Conceptual, discovery, development and implementation implications for psilocybin and related	5
Dalbavancin in the treatment of acute bacterial skin and skin structure and other infections: a safety evaluation	5
Pulmonary adverse events associated with amiodarone: a real-world pharmacovigilance study based on the FDA adverse event reporting system	5
An umbrella review of systematic reviews on contributory factors to medication errors in health-care settings	5
Compared of efficacy and safety of high-dose donepezil vs standard-dose donepezil among elderly patients with Alzheimer’s disease: a systematic review and meta-analysis	5
Safety of PARP inhibitors as maintenance therapy in ovarian cancer	5
Cyclin-dependent kinase 4/6 inhibitor-associated pulmonary toxicity: a disproportionality analysis from 2015 to 2023 based on the FAERS database	5
PD-1/PD-L1 inhibitors-associated cardiac adverse events: a retrospective and real-world study based on the FDA Adverse Event Reporting System (FAERS)	5
Pharmacovigilance insights into drug-induced cystitis: analysis of FDA data from 2004 to 2024	5
Post-marketing safety of panitumumab: a real-world pharmacovigilance study	5
Pre- and post-operative safety considerations for patients undergoing percutaneous nephrolithotomy	5
The safety of available pharmacotherapy for stroke prevention in atrial fibrillation	5
Correction	5
Comparative safety review of antithrombotic treatment options for patients with atrial fibrillation undergoing percutaneous coronary intervention	5
Quality of life in ovarian cancer patients treated with bevacizumab: a meta-analysis	5
Identification of novel signal of Raynaud’s phenomenon with Calcitonin Gene-Related Peptide(CGRP) antagonists using data mining algorithms and network pharmacological approaches	5
Infectious complications associated with immune and targeted anti-cancer therapies: a retrospective study of the FDA adverse events reporting system (FAERS)	5
Risk of serious skin and subcutaneous tissue disorders for nimesulide among the pediatric population: a jeopardy identified through the analysis of global individual case safety reports	5
Hematopoietic adverse events associated with PARP inhibitors: A FAERS database study	5
Serotonin 5-HT 2B receptor agonism and valvular heart disease: implications for the development of psilocybin and related agents	5
Incidence and risk of treatment-related fatal adverse events in cancer patients treated with antibody conjugated drugs: a systematic review and meta-analysis of randomized controlled trials	5
A narrative review of the comparative safety of disease-modifying anti-rheumatic drugs used for the treatment of rheumatoid arthritis	5
A comparative analysis of the safety profiles between inclisiran and other PCSK9 inhibitors from real-world evidence – what have we learned recently?	5
Safeguarding drug safety in neonates: addressing the impact of in-hospital medication administration errors through prevention and standardization	5
Reviewing the evidence surrounding preservative-free tafluprost/timolol fixed-dose combination therapy in open-angle glaucoma and ocular hypertension management: a focus on efficacy, safety, and toler	5
Post-marketing safety assessment of constipation drugs: a real-world pharmacovigilance study based on FAERS database	5
Priapism associated with anti-seizure medications: a pharmacovigilance study and a review of published cases	5
Efficacy and safety of racemic ketamine and esketamine for depression: a systematic review and meta-analysis	5
A real-world pharmacovigilance study of tafasitamab: data mining of the US food and drug administration adverse event reporting system	4
Adverse event profile of setmelanotide in obesity: an integrated assessment and systematic review using disproportionality analysis, case reports and meta-analysis	4
Do new drugs for diabetic macular edema offer a safer option?	4
New exploration of signal detection of Regional Risks from the perspective of data mining: a pharmacovigilance analysis based on spontaneous reporting data in Zhenjiang, China	4
Post-marketing safety monitoring of tirzepatide: a pharmacovigilance study based on the FAERS database	4
Efficacy and safety of sonidegib for the management of basal cell carcinoma: a drug safety evaluation	4
What does real-world data reveal about cangrelor’s safety? An analysis of FDA adverse event reporting system (FAERS) database	4
Efficacy and safety of omitting 5-fluorouracil bolus in combination chemotherapy regimens for gastrointestinal cancers: a systematic review and meta-analysis	4
Phosphodiesterase-5 inhibitors and hearing impairment: a disproportionality analysis using the US food and drug administration adverse event reporting system	4
Pharmacovigilance analysis of cardiac risks associated with Bruton tyrosine kinase inhibitors	4
Hepatitis B virus reactivation associated with Janus kinase (JAK) inhibitors: a retrospective study of pharmacovigilance databases and review of the literature	4
Actual drug-related harms in residential aged care facilities: a narrative review	4
Flu vaccination in multiple sclerosis patients: a monocentric prospective vaccine-vigilance study	4
Antiseizure medications as migraine preventatives: a call for action for a teratogenic and neurodevelopmental risk removal	4
Assessment of Riociguat-related adverse events: a disproportionality analysis utilizing the FDA adverse event reporting system database	4
Detection and analysis of signals of adverse events of memantine based on the US food and drug administration adverse event reporting system	4
Evaluating the Impact of Black Box Warning Updates on the Reporting of Drug-Related Adverse Events: a Cross Sectional Study of the FAERS Database	4
Constipation-predominant irritable bowel syndrome treatment options Linaclotide, Lubiprostone, Plecanatide, and Tenapanor: analysis of the FDA Adverse Event Reporting System (FAERS) database	4
Central serous chorioretinopathy secondary to drugs: a real-world pharmacovigilance study of the FDA adverse event reporting system (FAERS)	4
Severe cutaneous adverse reactions due to antibiotics therapy: a pharmacovigilance analysis of FDA adverse event reporting system events	4
A safety review of tyrosine kinase inhibitors for chronic myeloid leukemia	4
Evaluation of adverse events of bamlanivimab, bamlanivimab/etesevimab used for COVID-19 based on FAERS database	4
Safety issues of Donepezil combined with Memantine in Alzheimer’s disease population: real-world pharmacovigilance	4
Ultrasound in the management of aromatase inhibitor-associated plantar fasciitis	4
Post-marketing safety concerns with luspatercept: a disproportionality analysis of the FDA adverse event reporting system	4
Ondansetron induced blindness: a pharmacovigilance database study	4
Anaphylactic risk associated with iodinated and gadolinium-based contrast media	4
Real-world analysis of levetiracetam-associated rhabdomyolysis: insights from the FDA adverse event reporting system	4
Mining and analysis of adverse events associated with aducanumab: a real-world study using FDA Adverse Event Reporting System database	4
The evolution of real-world evidence in healthcare decision making	4
Immune checkpoint inhibitor-related gastrointestinal adverse events: a disproportionality analysis based on the FAERS database	4
Major adverse events associated with lipid reduction in inclisiran: a pharmacovigilance research of the FAERS database	4
Adverse drug reactions of intravesical instillation therapy for bladder cancer: based on FDA adverse event reporting system	4
Drug-Induced Thrombocytopenia Severity and Toxicity (DITPst): binary classification of drugs by human thrombocytopenia toxicity	4
Mining and analysis of amphotericin B adverse reaction signals: a real-world study based on the FAERS database	4
Fluoroquinolones: old drugs, putative new toxicities	4
Changing paradigms in detecting rare adverse drug reactions: from disproportionality analysis, old and new, to machine learning	4
Safety analysis of antineoplastic drugs for lung cancer: a retrospective analysis based on Shaanxi Province in Western China	4
The adverse reactions of bevacizumab in combination with the FOLFOX chemotherapy regimen in metastatic colorectal cancer	4
Mining and disproportionality analysis of adverse events signals for naltrexone based on real-world data from the FAERS database	4
Evaluation of the safety and efficacy of biosimilar recombinant growth hormone in children with growth hormone deficiency: non-inferiority, randomized, parallel, multicentric and Phase III trial	4